Choosing Multiple Myeloma Regimens
Gabriel Hinojosa, PharmD, BCOP, provides insights on selecting the best treatment regimen, and considers comorbidities, adverse events, and therapy modifications in multiple myeloma treatment.
EP: 1.Pharmacists in Multiple Myeloma Care: Essential Roles and Patient Support
EP: 2.Eligibility Factors in Multiple Myeloma Transplant
EP: 3.Multiple Myeloma Care: Pharmacist Team Collaboration
EP: 4.Multiple Myeloma Regimen Comparisons
EP: 5.Pharmacist's Role in Enhancing Multiple Myeloma Care
EP: 6.Choosing Multiple Myeloma Regimens
EP: 7.Pharmacists' Patient Counseling Role
EP: 8.Advanced Multiple Myeloma Treatments
EP: 9.Pharmacist-Led Care Transitions: Best Practices
EP: 10.Multiple Myeloma Challenges and Treatment Evolution
This is a video synopsis/summary of an Insights involving Gabriel Hinojosa, PharmD, BCOP.
Hinojosa addressed considerations in choosing among DRd (daratumumab, lenalidomide, dexamethasone), VRd (bortezomib, lenalidomide, dexamethasone), and KRd (carfilzomib, lenalidomide, dexamethasone) for patients with multiple myeloma based on comorbidities and adverse effects profiles. Daratumumab’s “more benign” adverse effects make it a common upfront choice, Hinojosa said, and the decision between VRd and KRd depends on patient-specific factors such as diabetes-related peripheral neuropathy or cardiovascular history. Discussing adverse events, Hinojosa highlighted infections, thrombotic events, gastrointestinal toxicity, and skin rash, emphasizing the need for routine monitoring and pharmacist-led education to increase patient awareness. Regarding clinical considerations for dose modifications or therapy switches, Hinojosa stressed evaluating changes due to toxicities or progressive disease, considering the patient’s response history and overall risk-benefit assessment. These insights guide personalized treatment approaches for optimizing outcomes in patients with multiple myeloma.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.
